A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

Summary

This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects must not have received prior systemic therapy for advanced HCC in keeping with the first-line setting of this study.

Timeline

Start

2018-04-26

Primary completion

2023-04-21

Completion

2026-03-09

Drugs

Indications